Menu Search
Equities

Cosmos Pharmaceutical Corp

3349:TYO

Cosmos Pharmaceutical Corp

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (JPY)7,042.00
  • Today's Change-78.00 / -1.10%
  • Shares traded86.00k
  • 1 Year change-10.49%
  • Beta0.0944
Data delayed at least 20 minutes, as of Nov 14 2024 03:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform4
Hold7
Sell0
Strong Sell0

Share price forecast in JPY

The 13 analysts offering 12 month price targets for Cosmos Pharmaceutical Corp have a median target of 8,300.00, with a high estimate of 10,000.00 and a low estimate of 6,650.00. The median estimate represents a 16.57% increase from the last price of 7,120.00.
High40.4%10,000.00
Med16.6%8,300.00
Low-6.6%6,650.00

Dividends in JPY

In 2024, Cosmos Pharmaceutical Corp reported a dividend of 60.00 JPY, which represents a 20.00% increase over last year. The 14 analysts covering the company expect dividends of 65.63 JPY for the upcoming fiscal year, an increase of 9.38%.
Div growth (TTM)20.00%
More ▼

Earnings history & estimates in JPY

On Oct 11, 2024, Cosmos Pharmaceutical Corp reported 1st quarter 2025 earnings of 102.74 per share. This result exceeded the 88.69 consensus of the 2 analysts covering the company and exceeded last year's 1st quarter results by 25.03%.
The next earnings announcement is expected on Jan 10, 2025.
Average growth rate+7.33%
Cosmos Pharmaceutical Corp reported annual 2024 earnings of 308.61 per share on Jul 12, 2024.
Average growth rate+4.36%
More ▼

Revenue history & estimates in JPY

COSMOS Pharmaceutical Corporation had 1st quarter 2025 revenues of 261.84m. This bettered the 261.11m consensus of the 9 analysts covering the company. This was 8.35% above the prior year's 1st quarter results.
Average growth rate+2.07%
COSMOS Pharmaceutical Corporation had revenues for the full year 2024 of 964.99m. This was 16.59% above the prior year's results.
Average growth rate+9.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.